So far, we have every reason to believe that a circular pathway hsa-miR19-3p/NKRF/NF-κB is likely to maintain the continuous activation of NF-κB in LC tissues of LC patients with COPD (As shown in Fig. 6). This evidence concerns the gene NFKB1 and laryngotracheoesophageal cleft.